Chinmaya IAS Academy – Current Affairs Chinmaya IAS Academy – Current Affairs
Related Articles
Psychedelic drugs, banned in India under the Narcotic Drugs and Psychotropic Substances Act, are emerging in research as promising ways to treat treatment-resistant depression and post-traumatic stress disorder
Psychedelics
- Psychedelics are a group of drugs that alter perception, mood, and thought-processing while a person is still clearly conscious.
- Psychedelics are non-addictive, non-toxic and compared to illicit drugs, they are less harmful to the end user.
- In India, the Narcotic Drugs and Psychotropic Substances Act 1985 prohibits the use of psychedelic substances.
- Ketamine, a dissociative anaesthetic with psychedelic properties, is used under strict medical supervision, for anaesthesia and treatment-resistant depression.
- A psychiatrist named Humphrey Osmond first used the term ‘psychedelic’ in 1957.
How do the drugs work in the body?
- An intriguing phenomenon called synaesthesia may occur, where the sensory modalities cross and the user may ‘hear colour’ or ‘see sounds’.
- Psychedelics are neither stimulants nor depressants of brain activity.
- Instead, they increase the cross-talk between different brain networks, and this correlates with the subjective effects of psychedelics.
Can such substances cause harm?
- Death due to direct toxicity of psychedelics has not been reported.
- Synthetic psychedelics have been associated with acute cardiac, central nervous system, and limb ischaemia, as well as serotonin syndrome.
- There have also been reports of death attributed directly to synthetic psychedelic use.
Recent breakthroughs:
- Recently, the results from a phase II psilocybin trial found that a single 25-mg dose of psilocybin reduced depression scores over three weeks in people with treatment-resistant depression.
- In 2017, the U.S. Food and Drug Administration (FDA) designated the use of 3,4-methylenedioxymethamphetamine, also known as MDMA, to be the breakthrough therapy in the treatment of post-traumatic stress disorder (PTSD).
- In 2018, the FDA had granted breakthrough therapy status to psilocybin for treatment-resistant depression as well.
Road Ahead:
- Although recent findings are encouraging, there remains uncertainty about where the psychedelic renaissance will take us.
- Psychedelic substances provide an intriguing avenue through which one can probe the broader constructs of creativity, spirituality, and consciousness, aside from their therapeutic effects.
- While not a panacea, psychedelic substances have certainly reinvigorated clinical and research interests, and have added to psychiatry’s ever-expanding therapeutic armamentarium.
- If larger phase III trials establish their safety and therapeutic efficacy, the FDA and other regulatory bodies may clear these agents for routine clinical use.
SOURCE: THE HINDU, THE ECONOMIC TIMES, PIB
